Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06967558 · ClinicalTrials.gov registry record · Phase 2
The Role of Islet GLP-1 in the Pathogenesis of Prediabetes
A Phase 2 study of PreDiabetes, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT06967558: Recruiting Phase 2 study of PreDiabetes, sponsored by Mayo Clinic.
NCT06967558 is a Phase 2 study of PreDiabetes that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 60 participants, below the 701-participant average among 149 other PreDiabetes trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06967558, a Phase 2 study of PreDiabetes, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
We recently demonstrated that blockade of Glucagon-Like Peptide-1's (GLP-1) receptor (GLP1R) results in changes in islet function without changes in circulating GLP-1. These effects are more pronounced in people with early type 2 diabetes (T2DM) in keeping with increased expression of PC-1/3 and GLP-1 that is observed in diabetic islets. However, its regulation is at present unknown. At present it is unknown if these abnormalities develop in prediabetes and whether they contribute to the phenotypes observed. In this experiment we will use blockade of GLP1R to probe the contribution of endogenous GLP-1 secretion to the regulation of fasting glucose and islet function in prediabetes.
Primary Outcome
The change in glucose necessary to suppress glucagon secretion by 50%
Conditions Studied
Interventions
- BIOLOGICAL Saline
- BIOLOGICAL Exendin 9-39
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-11-01 |
| Est. Completion | 2028-03-31 |
| Phase | Phase 2 |
What NCT06967558 shows while recruiting
NCT06967558 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 701-participant average among 149 other PreDiabetes trials with a reported enrollment target (91% lower).
The record links to 1 condition, with PreDiabetes appearing as the primary indexed condition, and to 2 interventions - of which Saline is the first listed.
NCT06967558 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06967558 about?
NCT06967558 is a clinical study titled "The Role of Islet GLP-1 in the Pathogenesis of Prediabetes". We recently demonstrated that blockade of Glucagon-Like Peptide-1's (GLP-1) receptor (GLP1R) results in changes in islet function without changes in circulating GLP-1. These effects are more pronounced in people with early type 2 diabetes (T2DM) in keeping with increased expression of PC-1/3 and GLP...
What is the current status of trial NCT06967558?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-11-01. Estimated completion is 2028-03-31.
What conditions does trial NCT06967558 study?
This clinical trial studies the following conditions: PreDiabetes.
What interventions are being tested in trial NCT06967558?
The interventions under investigation include: Saline (BIOLOGICAL), Exendin 9-39 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06967558?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06967558 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PreDiabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06967558's enrollment target sits among peer trials
60 90th of 149 higher than 54 of 149 other PreDiabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other PreDiabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mechanisms for Activation of Beige Adipose Tissue in Humans
RECRUITING · Phase 2
-
Social Determinants and a Diabetes Prevention Program Tailored for African Americans
RECRUITING · Phase 2
-
Long Term Impact of Time-Restricted Eating on Parameters of Cardiometabolic Health
RECRUITING · Phase 2
-
An Open-Label Pilot Intervention Trial to Prevent Diabetes in Prediabetic Adult Survivors of Childhood Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
Black Impact: The Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI